# ezDiatech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ezdiatech

- Industry: Medical Devices & Equipment
- Headquarters: Gyeonggi-do, South Korea
- Website: www.ezdiatech.com
- Latest round: Seed (Jun 1, 2019)
- Investors on record: 2

## About

Based in Gyeonggi-do, South Korea, and founded in 2016, ezDiatech also known as Easy Diatech operates as a developer of in vitro diagnostic technologies and solutions used for early diagnosis of diseases. In June 2019, the firm raised its seed funding led by investors KB Investment and Korea Tech Incubator for Startup, on being selected for Accelerator Investment-Driven Tech Incubator Program. The firm as of June 2023, is led by its CEOs Jung Yong-gyun and Lee Seok-joo.

The company provides ultra-high sensitivity multi-detection diagnostic solutions. The company’s flagship product, VEUS is a fully automatic diagnostic system that can perform immunoassays within 15 to 50 minutes, along with the features such as simultaneous implementation of multiple markers, high sensitivity of 1 pg per ml or less, and accurate diagnosis results of over 95%. VEUS is created using technologies such as original magnetic particles, quick response technology, fluorescence analysis module, and AI (artificial intelligence) multi-diagnosis analysis. In addition, Easy Diatech also offers RAPID, a pandemic disease diagnosis technology kit that enables Traumatic Brain Injury (TBI), Neurology multiple, and Respiratory Virus Multiple diagnoses through immunodiagnostic, and outline and item diagnosis through molecular diagnosis. The company’s rapid products include Covid-19 Ag, Ab, and Nab test kits, Dengue NS1, IgG, and IgM tests, etc.

## Funding rounds

- Seed, Jun 1, 2019 — KB Investment, Korea Tech Incubator for Startup

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Seed
- Korea Tech Incubator for Startup — Seed